Short Interest in Tiziana Life Sciences Ltd (NASDAQ:TLSA) Declines By 20.0%

Tiziana Life Sciences Ltd (NASDAQ:TLSA) was the target of a significant decrease in short interest in April. As of April 15th, there was short interest totalling 257,800 shares, a decrease of 20.0% from the March 31st total of 322,200 shares. Based on an average trading volume of 149,600 shares, the short-interest ratio is presently 1.7 days.

Tiziana Life Sciences Price Performance

NASDAQ:TLSA traded up $0.01 during mid-day trading on Tuesday, reaching $0.66. 174,340 shares of the company’s stock were exchanged, compared to its average volume of 147,235. Tiziana Life Sciences has a one year low of $0.41 and a one year high of $1.27. The business’s fifty day simple moving average is $0.52 and its two-hundred day simple moving average is $0.57.

Tiziana Life Sciences Company Profile

Tiziana Life Sciences Ltd, a biotechnology company, focuses on the discovery and development of molecules to treat human diseases in oncology and immunology. The company's lead product candidate in immunology is Foralumab (TZLS-401), a human anti-CD3 monoclonal antibody (mAb) for the treatment of Crohn's, graft versus host, ulcerative colitis, multiple sclerosis, type-1 diabetes, inflammatory bowel, psoriasis, and rheumatoid arthritis diseases.